LOSCOCCO, GIUSEPPE GAETANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 803
EU - Europa 559
AS - Asia 262
SA - Sud America 2
AF - Africa 1
Totale 1.627
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 795
IT - Italia 153
IE - Irlanda 112
RU - Federazione Russa 104
HK - Hong Kong 95
SE - Svezia 81
CN - Cina 62
CH - Svizzera 58
SG - Singapore 57
JO - Giordania 27
TW - Taiwan 17
DE - Germania 12
FI - Finlandia 12
GB - Regno Unito 11
CA - Canada 8
AT - Austria 4
ES - Italia 4
UA - Ucraina 4
BR - Brasile 2
FR - Francia 2
IN - India 2
JP - Giappone 2
EG - Egitto 1
PL - Polonia 1
SI - Slovenia 1
Totale 1.627
Salva come PNG Salva come JPEG
Città #
Dublin 112
Fairfield 101
Chandler 96
Ashburn 79
Hong Kong 61
Bern 58
Moscow 47
Altamura 42
Woodbridge 42
Lawrence 41
Seattle 37
Cambridge 31
Houston 27
Wilmington 26
Princeton 25
Buffalo 22
Shanghai 22
Singapore 22
New York 21
Boston 20
Florence 20
Beijing 15
Kent 14
Taipei 14
Ann Arbor 11
Fiesole 9
Helsinki 9
San Diego 9
Bremen 8
Andover 6
Boardman 6
Medford 6
Rome 6
Hangzhou 5
Los Angeles 5
San Jose 5
Toronto 5
Washington 5
Hillsboro 4
Napoli 4
Sesto Fiorentino 4
Vienna 4
West Jordan 4
Livorno 3
London 3
Reston 3
Barcelona 2
Cagliari 2
Chengdu 2
Cortona 2
Dearborn 2
Hefei 2
Jacksonville 2
Kilburn 2
Le Vigan 2
Maranello 2
Milan 2
New Taipei 2
Norwalk 2
Osteria del Gatto 2
Pisa 2
Pune 2
Recanati 2
Red Deer 2
Rimini 2
Sachigaoka 2
San Giovanni Valdarno 2
Sant'elpidio A Mare 2
Santa Croce sull'Arno 2
Seville 2
São Paulo 2
Abenberg 1
Bari 1
Berlin 1
Brugherio 1
Cairo 1
Caronno Pertusella 1
Catania 1
Catanzaro 1
Clifton 1
Cologno Monzese 1
Ferrara 1
Fiumicino 1
Guangzhou 1
Hounslow 1
Islington 1
Jinan 1
Jining 1
Kunming 1
Lappeenranta 1
Laurel 1
Leawood 1
Ljubljana 1
Monteriggioni 1
Montreal 1
New Taipei City 1
Pesaro 1
Rui'an 1
San Mateo 1
Sarcedo 1
Totale 1.198
Salva come PNG Salva come JPEG
Nome #
Germline transmission of LNKE208Q variant in a family with myeloproliferative neoplasms 114
A case of disseminated Blastic Plasmocytoid Dendritic Cell Neoplasm 99
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study 99
Kaposi Sarcoma in a patient treated with Ruxolitinib 95
Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative 91
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms 81
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera 62
A case of aleukemic mast cell leukemia with an underlying myeloproliferative neoplasm: Morphological and molecular characteristics of a highly aggressive disease 47
Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera 47
Integration of molecular information in risk assessment of patients with myeloproliferative neoplasms 44
BRAFV600E mutation in the wrong place: a case of concomitant polycythemia vera, hairy cell leukemia, and thyroid adenoma 44
Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases 44
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial 41
JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis 41
Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients 40
Impact of mutational profile on the management of myeloproliferative neoplasms: A short review of the emerging data 39
The HScore for secondary hemophagocytic lymphohistiocytosis, calculated without a marrow biopsy, is consistently low in patients with COVID-19 39
Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms 39
Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis 38
Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities 35
Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia 34
Lenalidomide: A double-edged sword for concomitant multiple myeloma and post-essential thrombocythemia myelofibrosis 34
Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis 33
ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera 31
Clinical, Molecular, and Histopathological Correlates in a Series of 24 Consecutive Cases of Suspected Myeloproliferative Neoplasms with a JAK2V617F Variant Allele Frequency≤ 1% 31
T-Cell Lymphoblastic Lymphoma Arising in the Setting of Myeloid/Lymphoid Neoplasms with Eosinophilia: LMO2 Immunohistochemistry as a Potentially Useful Diagnostic Marker 31
Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project 29
Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia 29
Mutations and thrombosis in essential thrombocythemia 28
Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis 27
Concomitant myeloproliferative neoplasm with eosinophilia, B and T cell lymphoblastic lymphoma/leukemia and mast cell proliferation driven by ZMYM2::FGFR1 rearrangement 24
Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis 22
Quick complete response achievement with venetoclax and azacitidine in a case of relapsed disseminated blastic plasmacytoid dendritic cell neoplasm 22
Secondary hemophagocytic lymphohistiocytosis, HScore and COVID-19 17
Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera 17
Successful use of caplacizumab in a case of refractory acquired thrombotic thrombocytopenic purpura following subacute thyroiditis 17
Skin Involvement by Hematological Neoplasms with Blastic Morphology: Lymphoblastic Lymphoma, Blastoid Variant of Mantle Cell Lymphoma and Differential Diagnoses 14
Bone marrow involvement in small cell lung cancer 14
Myeloid sarcoma: more and less than a distinct entity 11
A globally applicable "triple A" risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte count 11
Visceral Leishmaniasis 10
CALR mutation burden in essential thrombocythemia and disease outcome 10
Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives 8
The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis 6
SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates 5
Totale 1.694
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.153
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.153
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020169 0 5 1 21 26 25 26 23 20 10 10 2
2020/202188 6 3 24 20 2 3 2 6 8 4 8 2
2021/2022143 1 0 1 2 3 3 0 40 15 3 30 45
2022/2023619 51 117 40 28 28 86 67 30 56 10 15 91
2023/2024492 28 34 57 23 55 67 22 91 9 47 35 24
2024/2025130 84 46 0 0 0 0 0 0 0 0 0 0
Totale 1.694